 Home > Medical News > Medicines Company News > BeiGene will present its Hematology Oncology Clinical Development Program Update at the 64th American Society of Hematology Annual Meeting

BeiGene will present its Hematology Oncology Clinical Development Program Update at the 64th American Society of Hematology Annual Meeting

 Last Update: 2022-11-14
 Source: Internet
 Author: User

Tags

1 4 cyclohexadiene

end date

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

BeiGene (NASDAQ: BGNE; HKEx code: 06160; SSE: 688235) is a global biotechnology company
.
The Company announced on November 3 that it will present a series of clinical trial results and real-world data project progress
at the 64th Annual Meeting of the American Society of Hematology (ASH), New Orleans, December 10-14, 2022.
BeiGene is focused on developing innovative, affordable anti-oncology drugs for patients around the world, improving patient outcomes and increasing
accessibility.

Key presentations include:

● Results of a proof-of-concept Phase 1 trial of a novel B-cell lymphoma-2 (Bcl-2) inhibitor BGB-11417 for the treatment of patients with chronic lymphoblastic leukemia (CLL)/small lymphoblastic leukemia (SLL);

● Data on the long-term efficacy and safety of BRUKINSA (zebrutinib) in patients with relapsed/refractory (R/R) marginal zone lymphoma in the MAGNOLIA ® trial;

●A Phase 2 trial update showed that zebrutinib is effective and tolerated
in patients with B-cell malignancies who cannot tolerate acalabrutinib.

Mehrdad Mobasher, M.
D.
, Chief Medical Officer of Hematology, BeiGene, and Master of Public Health said, "BeiGene has laid a solid foundation
in innovative drug research and clinical development in hematological oncology.
At this year's ASH conference, we look forward to sharing BeiGene's extensive global development projects and the wealth of data
they present.
" We look forward to demonstrating BeiGene's expertise and drive for innovation, from the Phase 1 trial data of the new Bcl-2 inhibitor BGB-11417 to multiple data reports
confirming BRUKINSA's ® significant clinical efficacy and consistent safety profile across a variety of B-cell malignancies.
" "

Other demonstrations focused on combination therapies and pipeline strength include:

● Preliminary safety and efficacy data of zebrutinib combined with lenalidomide in patients with R/R diffuse large B-cell lymphoma;

● Poster presentation of multiple phase 1 trial results of BGB-11417, a novel Bcl-2 inhibitor, showing that it has good efficacy and controllable safety characteristics in the treatment of B-cell lymphoma and myeloid leukemia;

● Safety and efficacy data
of zebrutinib combined with PI3Kδ inhibitor zandelisib in patients with R/R follicular lymphoma or mantle cell lymphoma.

About BRUKINSA ®

BRUKINSA ® (zebrutinib) is a Bruton's tyrosine kinase (BTK) small molecule inhibitor independently developed by BeiGene scientists and is currently undergoing extensive clinical trials worldwide as a monotherapy and in combination with other therapies for the treatment of a variety of B-cell malignancies
.
BRUKINSA ® is designed to achieve targeted, sustained inhibition
of BTK protein by optimizing bioavailability, half-life and selectivity.
With differentiated pharmacokinetic profiles from other approved BTK inhibitors, BRUKINSA ® has been shown to inhibit malignant B cell proliferation
in multiple disease-related tissues.

BRUKINSA ® has conducted an extensive global clinical development program and has now conducted 35 trials in 28 markets worldwide, enrolling more than 4,500 participants
.
To date, BRUKINSA ® has been approved
in more than 55 countries and territories, including the United States, China, the European Union, Switzerland, the United Kingdom, Canada, Australia and other international markets.

About BGB-11417

BGB-11417 is a potent, highly selective B-cell lymphoma 2 (BCL-2) inhibitor designed to produce deeper, longer-lasting target inhibition
.
BGB-11417 has shown higher potency (greater than 10-fold difference) and target selectivity in both preclinical studies and tumor models compared to venetoclax^[i].

[i] Nan Hu, Yunhang Guo, Hai Xue, Ye Liu, Yin Guo, Fan Wang, Xiaomin Song, Ying Guo, Shuaishuai Chen, Haipeng Xu, Taichang Zhang, Yanwen Ma, Xuebing Sun, Yuan Hong, Yutong Zhu, Aiying Xu, Zhenzhen Cheng, Haimei Xing, Zhiwei Wang, Xuesong Liu, Lai Wang; Abstract 3077: Preclinical characterization of BGB-11417, a potent and selective Bcl-2 inhibitor with superior antitumor activities in haematological tumor models.
Cancer Res 15 August 2020; 80 (16_Supplement): 3077.
https://doi.
org/10.
1158/1538-7445.
AM2020-3077

={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"Share to:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)];

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.